A Dose Ranging Study to Examine Testagen® TDS-Testosterone 5%
Status:
Enrolling by invitation
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This study is a continuation of previous studies done in healthy volunteers to prove the
efficacy of delivering Testosterone, the male hormone, rapidly across intact skin in s series
of doses from low to high in men with low-to-no natural testosterone production to measure
their response to the varying doses. The results of this study will inform further studies
which will be longer in length, as to the starting doses. The study will be conducted in
London, U.K. at the Advanced Therapies Centre, The London Clinic.